Meeting
2022 ASCO Annual Meeting
EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors.
Authors
Marina Chiara Garassino
University of Chicago, Department of Medicine, Chicago, IL
Marina Chiara Garassino , Douglas Reznick , Steven Y. Liu , Niels Reinmuth , Nicolas Girard , Filippo de Marinis , Sabeen Fatima Mekan , Riddhi Patel , Michelle Ding , Luis Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05089734
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9149)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9149
Abstract #
TPS9149
Poster Bd #
129a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
First Author: Benjamin Besse
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly